The Prostate Cancer Clinical Trials Consortium: Clinical Research Site Application
Abstract
Purpose: The purpose of the PCCTC is to accelerate the development of novel therapeutics for prostate cancer patients, both by bringing own areas of expertise and contributing substantially to the activity of the consortium in the areas of biomarker development, androgen receptor targeted therapies, aggressive variant/neuroendocrine prostate cancer, and theranostics/novel molecular imaging. Results: During the reporting period, 28 patients were accrued across six PCCTC clinical trials, including two trials led by UCSF. Two UCSF-led LOIs have been submitted, including a trial of PSMA-directed SBRT trial in oligometastatic CRPC presented at the Scientific Oversight Committee in October 2019 and an additional immunotherapy trial with combination of pembrolizumab plus talabostat.
Document Details
- Document Type
- Technical Report
- Publication Date
- Oct 01, 2020
- Accession Number
- AD1125847
Entities
People
- Rahul Aggarwal
Organizations
- University of California, San Francisco